Sage Journals: Discover world-class research

Abstract

We investigated whether natural killer (NK) cells in the tumor microenvironment have a radiosensitization effect. The radiosensitization effect of combined CpG and Herceptin^® (Genentech, Inc., South San Francisco, CA) (CpG/Herceptin), given before or after radiation, was evaluated by using a murine colon cancer cell line overexpressing human HER2/neu, CT26HER2/neu. In vitro radiosensitization effects were investigated by coculture of CT26HER2/neu with splenocytes, CpG, and Herceptin before applying radiation. Tumor cells, cocultured with CpG-pretreated splenocytes and Herceptin, were more vulnerable to radiation damage. In BALB/c mice injected with CT26HER2/neu, CpG/Herceptin administered before radiotherapy was associated with a better retardation of tumor growth than when administered after radiotherapy. The radiosensitization effect was significantly abrogated by NK-cell depletion, indicating that NK cells play an essential role in it. Further, surviving mice treated with CpG or CpG/Herceptin and reverse transcriptase were resistant to renewed tumor challenge, suggesting the presence of an induced immune response to the tumor. Neoadjuvant immunotherapy with CpG/Herceptin may improve response to radiotherapy of HER2/neu-expressing tumors.

Get full access to this article

View all access options for this article.

References

Zitvogel

, Apetoh

, Ghiringhelli

et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol, 2008; 8:59.

Apetoh

, Ghiringhelli

, Tesniere

et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007; 13:1050.

Prendergast

, Jaffee

. Cancer immunologists and cancer biologists: Why we didn't talk then but need to now. Cancer Res, 2007; 67:3500.

McBride

, Chiang

, Olson

et al. A sense of danger from radiation. Radiat Res, 2004; 162:1.

Koski

, Czerniecki

. Combining innate immunity with radiation therapy for cancer treatment. Clin Cancer Res, 2005; 11:7.

Slamon

. Proto-oncogenes and human cancers. NEJM, 1987; 317:955.

Vogel

, Cobleigh

, Tripathy

et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 2002; 20:719.

Liang

, Lu

, Jin

et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther, 2003; 2:1113.

Takeshita

, Gursel

, Ishii

et al. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol, 2004; 16:17.

10.

Klinman

. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol, 2004; 4:249.

11.

Krieg

. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep, 2004; 6:88.

12.

Carpentier

, Xie

, Mokhtari

et al. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res, 2000; 6:2469.

13.

Tormo

, Ferrer

, Bosch

et al. Therapeutic efficacy of antigen-specific vaccination and Toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res, 2006; 66:5427.

14.

Jahrsdorfer

, Weiner

. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther, 2008; 3:27.

15.

Jahrsdorfer

, Weiner

. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin Oncol, 2003; 30:476.

16.

Wang

, Rayburn

, Wang

et al. Immunomodulatory oligonucleotides as novel therapy for breast cancer: Pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther, 2006; 5:2106.

17.

Milas

, Mason

, Ariga

et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res, 2004; 64:5074.

18.

Mason

, Ariga

, Neal

et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res, 2005; 11:361.

19.

Wang

, Tsang

, Chi

et al. Synergistic antitumor effect of combination radio- and immunotherapy by electro-gene therapy plus intratumor injection of dendritic cells. Cancer Lett, 2008; 266:275.

20.

Chi

, Wang

, Chen

et al. Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model. J Nucl Med, 2001; 42:345.

21.

Okunieff

, Morgan

, Niemierko

et al. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys, 1995; 32:1227.

22.

Ballas

, Rasmussen

, Krieg

. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol, 1996; 157:1840.

23.

Musolino

, Naldi

, Bortesi

et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol, 2008; 26:1789.

24.

van Ojik

, Bevaart

, Dahle

et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res, 2003; 63:5595.

25.

Meng

, Carpentier

, Chen

et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer, 2005; 116:992.

26.

Roses

, Xu

, Koski

et al. Radiation therapy and Toll-like receptor signaling: Implications for the treatment of cancer. Oncogene, 2008; 27:200.

27.

Merrell

, Ilvesaro

, Lehtonen

et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res, 2006; 4:437.

Neoadjuvant Immunotherapy Enhances Radiosensitivity Through Natural Killer Cell Activation

Abstract

Get full access to this article

References